APP and Alzheimer disease: According to studies in AD mouse models based on APP and PS1 mutations, both Ca2+ hyperactivity and hypoactivity have been described at the neuronal level, with hyperactivity dominating the early stage of the disease, being brought by soluble Aβ10–13.